Selective estrogen receptor modifiers (SERMs) such as tamoxifen, raloxifene, and toremifene, as well as aromatase inhibitors (AIs) like anastrozole, letrozole, and exemestane, are included in adjuvant hormonal therapy for BC in postmenopausal women2. The gene discussed is CYP19A1; the disease is breast cancer.